Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Virpax Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VRPX
Nasdaq
8731
https://virpaxpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals Reports 2023 Year-End Results
- Mar 26th, 2024 11:30 am
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
- Feb 27th, 2024 12:31 pm
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
- Feb 27th, 2024 12:30 pm
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
- Feb 7th, 2024 12:30 pm
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
- Dec 29th, 2023 12:30 pm
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
- Nov 17th, 2023 12:10 pm
Virpax Pharmaceuticals Announces Leadership Transition
- Nov 17th, 2023 12:00 pm
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments
- Nov 15th, 2023 9:15 pm
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
- Oct 31st, 2023 12:58 pm
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
- Oct 12th, 2023 12:02 pm
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
- Oct 2nd, 2023 12:58 pm
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies
- Sep 27th, 2023 12:58 pm
Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
- Sep 26th, 2023 12:58 pm
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
- Sep 21st, 2023 2:00 pm
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
- Sep 18th, 2023 11:58 am
Virpax Pharmaceuticals Updates on Litigation
- Sep 5th, 2023 1:00 pm
Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Aug 28th, 2023 12:58 pm
Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
- Aug 14th, 2023 1:00 pm
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method
- Aug 10th, 2023 12:58 pm
Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023
- Jul 24th, 2023 11:00 am
Scroll